Evidence map›Paper›PMID 37133642›Full record

ArticleEndocrine2023

Denosumab for osteoporosis in patients with primary hyperparathyroidism and mild-to-moderate renal insufficiency.

Sofia Gronskaya, Zhanna Belaya, Liudmila Rozhinskaya, Elizaveta Mamedova, Maria Vorontsova, Alexander Solodovnikov, Olga Golounina, Galina Melnichenko

Abstract read
PubMed Publisher
In one paragraph

Article in Endocrine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 1 country.

Sofia GronskayaEndocrinology Research Centre, Department of Neuroendocrinology and Bone Disease, Moscow, Russia.ORCID 0000-0001-7055-2407
Zhanna BelayaEndocrinology Research Centre, Department of Neuroendocrinology and Bone Disease, Moscow, Russia. jannabelaya@gmail.com.ORCID 0000-0002-6674-6441
Liudmila RozhinskayaEndocrinology Research Centre, Department of Neuroendocrinology and Bone Disease, Moscow, Russia.ORCID 0000-0001-7041-0732
Elizaveta MamedovaEndocrinology Research Centre, Department of Neuroendocrinology and Bone Disease, Moscow, Russia.ORCID 0000-0002-9783-3599
Maria VorontsovaEndocrinology Research Centre, Department of Neuroendocrinology and Bone Disease, Moscow, Russia.ORCID 0000-0002-9124-294X
Alexander SolodovnikovUral State Medical Academy, Ekaterinburg, Russia.ORCID 0000-0002-4564-2168
Olga GolouninaSechenov First Moscow State Medical University, Moscow, Russia.ORCID 0000-0003-2320-1051
Galina MelnichenkoEndocrinology Research Centre, Department of Neuroendocrinology and Bone Disease, Moscow, Russia.ORCID 0000-0002-5634-7877
Endocrinology Research Center · RULomonosov Moscow State University · RUResearch Center of Neurology · RUSechenov University · RUUral State Medical University · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeWe aimed to assess the efficacy and safety of denosumab in postmenopausal women with primary hyperparathyroidism (PHPT)-related osteoporosis and chronic kidney disease (CKD).

methodsWomen over 50 years of age with PHPT or postmenopausal osteoporosis (PMO) were retrospectively recruited into this longitudinal study. These PHPT and PMO groups were further categorized into subgroups based on the presence of CKD (Glomerular filtration rate (GFR) < 60 mL/min/1.73 m

results145 postmenopausal women median age 69 [63;77] were recruited and assigned to one of the subgroups: PHPT patients with CKD (n = 22), PHPT patients without CKD (n = 38), PMO patients with CKD (n = 17) and PMO patients without CKD (n = 68). Denosumab treatment significantly increased BMD in patients with PHPT-related osteoporosis and CKD: median T-score L1-L4 from -2.0 to -1.35 (p < 0.001), femur neck from -2.4 to -2.1 (p = 0.012), radius 33% from -3.2 to -3 (p < 0.05)) at 24 months. Changes in BMD were similar in all four studied groups compared to baseline. A marked decline in calcium was noted in the primary study group of PHPT with CKD (median ΔCa = -0.24 mmol/L p < 0.001), compared to PHPT without CKD (median ΔCa = -0.08 mmol/L p < 0.001) and PMO with or without CKD. Denosumab treatment was well-tolerated with no serious adverse events.

conclusionDenosumab treatment was similarly effective at increasing BMD in patients with PHPT and PMO with and without renal insufficiency. The calcium lowering effects of denosumab were most significant in patients with PHPT and CKD. The safety of denosumab did not differ among participants with and without CKD.

Indexed as

Bone Density Conservation AgentsHyperparathyroidism, PrimaryOsteoporosisOsteoporosis, PostmenopausalRenal InsufficiencyRenal Insufficiency, ChronicAgedBone DensityCalciumDenosumabFemaleHumansLongitudinal StudiesMiddle AgedRetrospective StudiesBone Density Conservation AgentsCalciumDenosumabCalcium levelsChronic kidney diseaseDenosumabOsteoporosisPrimary hyperparathyroidismRenal insufficiency

Identifiers

PMID37133642
OpenAlexW4367834935

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.